array:22 [ "pii" => "S0213005X24002969" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2024.08.004" "estado" => "S200" "fechaPublicacion" => "2024-10-08" "aid" => "2876" "copyright" => "Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "cor" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:16 [ "pii" => "S0213005X24003045" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2024.08.012" "estado" => "S200" "fechaPublicacion" => "2024-10-09" "aid" => "2884" "documento" => "article" "crossmark" => 0 "subdocumento" => "rev" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Nuevas recomendaciones de vacunación frente a COVID-19 en España: optimización para las próximas temporadas" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1832 "Ancho" => 2466 "Tamanyo" => 347973 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Recommendations to implement in COVID-19 vaccination for next vaccination seasons.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pilar Arrazola, María Fernández Prada, Ángel Gil, José Gómez Rial, Cristina Hernán, Rosario Menéndez, Antoni Trilla, Raúl Ortiz de Lejarazu" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Pilar" "apellidos" => "Arrazola" ] 1 => array:2 [ "nombre" => "María" "apellidos" => "Fernández Prada" ] 2 => array:2 [ "nombre" => "Ángel" "apellidos" => "Gil" ] 3 => array:2 [ "nombre" => "José" "apellidos" => "Gómez Rial" ] 4 => array:2 [ "nombre" => "Cristina" "apellidos" => "Hernán" ] 5 => array:2 [ "nombre" => "Rosario" "apellidos" => "Menéndez" ] 6 => array:2 [ "nombre" => "Antoni" "apellidos" => "Trilla" ] 7 => array:2 [ "nombre" => "Raúl" "apellidos" => "Ortiz de Lejarazu" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X24003045?idApp=UINPBA00004N" "url" => "/0213005X/unassign/S0213005X24003045/v1_202410091022/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S0213005X12002522" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2012.06.016" "estado" => "S200" "fechaPublicacion" => "2013-04-19" "aid" => "796" "copyright" => "Elsevier España, S.L." "documento" => "simple-article" "crossmark" => 0 "subdocumento" => "ret" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 232 "formatos" => array:3 [ "EPUB" => 15 "HTML" => 111 "PDF" => 106 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "WITHDRAWN: Executive summary. Consensus document of National AIDS Plan Secretariat/AIDS Expert Group on healthcare assistance for HIV infected women" "tienePdf" => "en" "tieneTextoCompleto" => 0 "tieneResumen" => "en" "contieneResumen" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Rosa Polo" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Rosa" "apellidos" => "Polo" ] 1 => array:1 [ "colaborador" => "Expert Panel of the AIDS Study Group/Spanish AIDS Plan" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X12002522?idApp=UINPBA00004N" "url" => "/0213005X/unassign/S0213005X12002522/v1_201304191723/en/main.assets" ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letter to the Editor</span>" "titulo" => "Accidental intravenous probiotic injection in an immunocompromised patient: Implications and consequences" "tieneTextoCompleto" => true "saludo" => "Dear Editor," "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Idoia Bilbao, María Pascual, José Ramón Yuste, José Luis del Pozo" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Idoia" "apellidos" => "Bilbao" "email" => array:1 [ 0 => "ibilbaodelolmo@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "María" "apellidos" => "Pascual" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "José Ramón" "apellidos" => "Yuste" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] 3 => array:3 [ "nombre" => "José Luis" "apellidos" => "del Pozo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Infectious Diseases Division, Clinica Universidad de Navarra, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Department of Internal Medicine, Clinica Universidad de Navarra, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Administración accidental intravenosa de probióticos en un paciente inmunodeprimido: implicaciones y consecuencias" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Upon reviewing the study conducted by Monnerat et al.,<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> on accidental intravenous probiotic injection in an otherwise healthy patient, we aim to contribute to the existing body of knowledge by presenting a similar scenario involving an immunocompromised individual. To our knowledge, the other published cases of bacteremia caused by <span class="elsevierStyleItalic">Bacillus clausii</span> are related to the oral administration of the probiotic.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">2–7</span></a> Of these, four are related to the pediatric population<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">2–5</span></a> and two to the adult population.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">We present a 64-year-old male diagnosed with chemorefractory gastric lymphoma, who presented to our center for CAR-T cell therapy. While preparing the treatment protocol, the patient was urgently admitted on September 14th, 2022, due to gastrointestinal bleeding and a fever of 39<span class="elsevierStyleHsp" style=""></span>°C. A blood culture conducted during the diagnostic work-up revealed the presence of <span class="elsevierStyleItalic">B. clausii</span>. Analysis shows that it was susceptible to levofloxacin (CMI 0.38), vancomycin (CMI 0.75), linezolid and tedizolid (CMI 0.75). However, it was resistant to meropenem and erythromycin. Antimicrobial susceptibility was interpreted following EUCAST 2022 Clinical Breakpoints (V. 12.0).</p><p id="par0015" class="elsevierStylePara elsevierViewall">Notably, the patient disclosed that he had been hospitalized in his home country (Ghana) on August 4th (Day 0), 2022, due to febrile neutropenia, which was treated with antibiotic therapy. Moreover, he started with profuse diarrhea, so that, he inadvertently received parenterally Enterogermina®.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Despite multiple courses of antibiotherapy (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>), bacteremia persisted. On September 23rd (Day 50), we conducted an echocardiogram, which did not reveal endocarditis. A whole-body PET-CT scan undergone October 7th (Day 64) demonstrated tumor progression and focal hyperenhancement of an ulcer in the upper limb, which corresponded to the site of the previous intravenous infusion of the probiotic. Subsequently, an ultrasonographic study performed one day later confirmed the presence of thrombophlebitis in the basilic vein. Given its potential as a spore production reservoir, surgical excision was promptly performed. The removed material revealed necrotic tissue in the hystological examination without any isolations in the microbiological cultures of the tissue. Moreover, the isolation of <span class="elsevierStyleItalic">B. clausii</span> in blood persisted after the material removal.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0025" class="elsevierStylePara elsevierViewall">Since bacteriemia was still present, and according to Khatri AM et al.,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a> we decided to start with Fidaxomicin as an anti-sporicide, as previously reported.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a> However, our attempts to utilize this approach were unsuccessful due to the inability to detect <span class="elsevierStyleItalic">B. clausii</span> in feces. Stool cultures consistently yielded negative results, and it should be noted that antibiotics of this nature primarily exert a local action.</p><p id="par0030" class="elsevierStylePara elsevierViewall">A subsequent whole-body PET-CT scan conducted on October 31st (Day 88) revealed tumor progression, with no evidence of any infectious involvement. The presence of persistent bacteremia ruled out the possibility of CART-cell therapy. Consequently, it was decided to administer conventional chemotherapy for the patient's underlying condition during their hospitalization period. This approach resulted in an improvement in the patient's clinical status.</p><p id="par0035" class="elsevierStylePara elsevierViewall">The patient was discharged on December 7th (Day 125), with regular outpatient monitoring of his clinical condition and ongoing treatment with Levofloxacin and Tedizolid. In subsequent follow-up visits, although bacteremia persisted, the patient remained asymptomatic, and antibiotic therapy was continued without modifications.</p><p id="par0040" class="elsevierStylePara elsevierViewall">On January 26th (Day 175), the patient was admitted with febrile neutropenia. During the entire follow-up period, the patient underwent periodic blood cultures, with a total of 27 blood cultures, all of which were positive. Interestingly, after the 27 positive blood cultures, no bacterial isolates were detected in the subsequent blood cultures. For each blood culture, 4 flasks (2 aerobic and 2 anaerobic) were submitted. The 2 aerobic flasks were positive with a positivity time of approximately 26<span class="elsevierStyleHsp" style=""></span>h. The identification method was by mass spectroscopy (Vitek-MS; bioMérieux).</p><p id="par0045" class="elsevierStylePara elsevierViewall">The bacteremia was ultimately resolved after a prolonged duration of antibiotic therapy, lasting 175 days. During this period, the patient received CART-cell therapy for his underlying disease. Unfortunately, two months later, the patient died due to the progression of his oncologic condition.</p><p id="par0050" class="elsevierStylePara elsevierViewall">Enterogermina® is an oral probiotic formulation containing 2 billion spores of <span class="elsevierStyleItalic">B. clausii.</span><span class="elsevierStyleItalic">B. clausii</span> is an aerobic gram-positive spore-forming bacillus<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">8,9</span></a> known for its survival in the acidic environment of the stomach and colonize the intestine even in the presence of antibiotics. Previously, accidental intravenous injection of Enterogermina® has been reported once<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> in an otherwise healthy outpatient, resulting in bacteremia that resolved after 5 months. To gather additional information and potential unpublished cases, similar to Monnerat et al.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">1</span></a> we reached out to Sanofi-Aventis, the company manufacturing the probiotic. However, the company could not provide specific treatment protocols beyond referring to the published case. Furthermore, they reported that no deaths have been associated with this administration error. In order to prevent future mistakes related to Enterogermina® administration, the company made modifications to the product labeling.</p><p id="par0055" class="elsevierStylePara elsevierViewall">The accidental intravenous administration of Enterogermina® in an immunocompromised patient raises significant clinical considerations. This case highlights the potential risks associated with medication errors and emphasizes the importance of strict adherence to treatment protocols. Persistent and refractory bacteremia associated with intravenous administration of Enterogermina®, although rare, is a serious complication that could be mitigated by modifying its labeling or even its commercial presentation. In both the present case and the previously reported one, blood cultures remained positive for 5 months, necessitating the implementation of alternative therapeutic strategies.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "fx1.jpeg" "imagenAlto" => 693 "imagenAncho" => 2500 "imagenTamanyo" => 121858 ] ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical findings, blood culture (BC) and antibiotic therapy chronology.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:9 [ 0 => array:3 [ "identificador" => "bib0050" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What happens after an accidental intravenous probiotic injection?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "N. Monnerat" 1 => "A.C. Lambert" 2 => "D. Genné" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2019.11.027" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2019" "volumen" => "26" "paginaInicial" => "517" "paginaFinal" => "518" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31805378" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0055" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A tale of caution: prolonged <span class="elsevierStyleItalic">Bacillus clausii</span> bacteraemia after probiotic use in an immunocompetent child" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Khatri" 1 => "S. Rai" 2 => "C. Shank" 3 => "A. McInerney" 4 => "B. Kaplan" 5 => "S.H.F. Hagmann" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Access Microbiol" "fecha" => "2021" "volumen" => "3" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0060" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">Bacillus clausii</span> bacteremia after probiotic usage in a pediatric patient" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Erbaş İC" 1 => "B. Nişancı" 2 => "B. Gür" 3 => "B.B. Makay" 4 => "O.T. İnce" 5 => "N. Belet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/00099228231207306" "Revista" => array:6 [ "tituloSerie" => "Clin Pediatr (Phila)" "fecha" => "2024" "volumen" => "63" "paginaInicial" => "183" "paginaFinal" => "186" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37850558" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0065" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Septicemia due to <span class="elsevierStyleItalic">Bacillus clausii</span> after the use of probiotics. A complication to keep in mind" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Muñoz" 1 => "G.E. Castaño" 2 => "R. Esquivel Suman" 3 => "M. Alvarado" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.32641/andespediatr.v94i3.4417" "Revista" => array:6 [ "tituloSerie" => "Andes Pediatr" "fecha" => "2023" "volumen" => "94" "paginaInicial" => "379" "paginaFinal" => "385" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37909941" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0070" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">Bacillus clausii</span> septicemia in a pediatric patient after treatment with probiotics" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S. Joshi" 1 => "S. Udani" 2 => "S. Sen" 3 => "S. Kirolikar" 4 => "A. Shetty" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/INF.0000000000002350" "Revista" => array:6 [ "tituloSerie" => "Pediatr Infect Dis J" "fecha" => "2019" "volumen" => "38" "paginaInicial" => "e228" "paginaFinal" => "e230" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31033906" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0075" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bacteremia after <span class="elsevierStyleItalic">Bacillus clausii</span> administration for the treatment of acute diarrhea: a case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.P. García" 1 => "J.A. Hoyos" 2 => "J.A. Alzate" 3 => "E. Cristancho" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.7705/biomedica.5662" "Revista" => array:7 [ "tituloSerie" => "Biomedica" "fecha" => "2021" "volumen" => "41" "numero" => "Suppl. 2" "paginaInicial" => "13" "paginaFinal" => "20" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34669274" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0080" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "When good bacteria behave badly: a case report of <span class="elsevierStyleItalic">Bacillus clausii</span> sepsis in an immunocompetant adult" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "I. Princess" 1 => "T. Natarajan" 2 => "S. Ghosh" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Access Microbiol" "fecha" => "2020" "volumen" => "2" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0085" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Enterogermina®. 09/15/2021: Sanofi; 2021." ] ] ] 8 => array:3 [ "identificador" => "bib0090" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Composite genome sequence of <span class="elsevierStyleItalic">Bacillus clausii</span>, a probiotic commercially available as Enterogermina®, and insights into its probiotic properties" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "I. Khatri" 1 => "G. Sharma" 2 => "S. Subramanian" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12866-019-1680-7" "Revista" => array:5 [ "tituloSerie" => "BMC Microbiol" "fecha" => "2019" "volumen" => "19" "paginaInicial" => "307" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31888501" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/0213005X/unassign/S0213005X24002969/v1_202410080946/en/main.assets" "Apartado" => null "PDF" => "https://static.elsevier.es/multimedia/0213005X/unassign/S0213005X24002969/v1_202410080946/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X24002969?idApp=UINPBA00004N" ]
Información de la revista
Compartir
Descargar PDF
Más opciones de artículo
Letter to the Editor
Disponible online el 8 de octubre de 2024
Accidental intravenous probiotic injection in an immunocompromised patient: Implications and consequences
Administración accidental intravenosa de probióticos en un paciente inmunodeprimido: implicaciones y consecuencias